Epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 virus-like particles in cervical HPV-16 DNA-positive and - negative women

L. Wideroff, M. H. Schiffman, R. Hoover, R. E. Tarone, B. Nonnenmacher, N. Hubbert, R. Kirnbauer, C. E. Greer, A. T. Lorincz, M. M. Manos, A. G. Glass, D. R. Scott, Mark E. Sherman, J. Buckland, D. Lowy, J. Schiller

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

The epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 L1/L2 virus-like particles (VLPs) were assessed separately in HPV-16 DNA-positive and -negative women participating in a nested case- control study of incident cervical neoplasia. Seventy-four women with cervical HPV-16 DNA and 656 cytologically normal HPV-16 DNA-negative subjects were interviewed and tested at two time points for viral DNA and once (at the later time) for VLP seroreactivity. Among subjects who were currently HPV-16 DNA-negative, seroreactivity odds ratios increased from 2.9 for 2-5 male sex partners (vs. 0 or 1) to 5.4 for 6-9 partners and 14.0 for ≤10. Thus, prior cervical infection may be a major determinant of seroreactivity in HPV-16 DNA-negative women. This trend was not observed in HPV-16 DNA-positive subjects. Seroreactivity was independently associated with oral contraceptive use, particularly in HPV-16 DNA-negative subjects with use for ≤10 years. Consequently, a possible role for virus-steroid hormone interactions in seroconversion is suggested.

Original languageEnglish (US)
Pages (from-to)937-943
Number of pages7
JournalJournal of Infectious Diseases
Volume174
Issue number5
StatePublished - 1996
Externally publishedYes

Fingerprint

Papillomaviridae
Epidemiologic Factors
Human papillomavirus 16
Virion
DNA
Viral DNA
Oral Contraceptives
Case-Control Studies

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Wideroff, L., Schiffman, M. H., Hoover, R., Tarone, R. E., Nonnenmacher, B., Hubbert, N., ... Schiller, J. (1996). Epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 virus-like particles in cervical HPV-16 DNA-positive and - negative women. Journal of Infectious Diseases, 174(5), 937-943.

Epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 virus-like particles in cervical HPV-16 DNA-positive and - negative women. / Wideroff, L.; Schiffman, M. H.; Hoover, R.; Tarone, R. E.; Nonnenmacher, B.; Hubbert, N.; Kirnbauer, R.; Greer, C. E.; Lorincz, A. T.; Manos, M. M.; Glass, A. G.; Scott, D. R.; Sherman, Mark E.; Buckland, J.; Lowy, D.; Schiller, J.

In: Journal of Infectious Diseases, Vol. 174, No. 5, 1996, p. 937-943.

Research output: Contribution to journalArticle

Wideroff, L, Schiffman, MH, Hoover, R, Tarone, RE, Nonnenmacher, B, Hubbert, N, Kirnbauer, R, Greer, CE, Lorincz, AT, Manos, MM, Glass, AG, Scott, DR, Sherman, ME, Buckland, J, Lowy, D & Schiller, J 1996, 'Epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 virus-like particles in cervical HPV-16 DNA-positive and - negative women', Journal of Infectious Diseases, vol. 174, no. 5, pp. 937-943.
Wideroff, L. ; Schiffman, M. H. ; Hoover, R. ; Tarone, R. E. ; Nonnenmacher, B. ; Hubbert, N. ; Kirnbauer, R. ; Greer, C. E. ; Lorincz, A. T. ; Manos, M. M. ; Glass, A. G. ; Scott, D. R. ; Sherman, Mark E. ; Buckland, J. ; Lowy, D. ; Schiller, J. / Epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 virus-like particles in cervical HPV-16 DNA-positive and - negative women. In: Journal of Infectious Diseases. 1996 ; Vol. 174, No. 5. pp. 937-943.
@article{6eef859106cb406c9d3dc9ab83932856,
title = "Epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 virus-like particles in cervical HPV-16 DNA-positive and - negative women",
abstract = "The epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 L1/L2 virus-like particles (VLPs) were assessed separately in HPV-16 DNA-positive and -negative women participating in a nested case- control study of incident cervical neoplasia. Seventy-four women with cervical HPV-16 DNA and 656 cytologically normal HPV-16 DNA-negative subjects were interviewed and tested at two time points for viral DNA and once (at the later time) for VLP seroreactivity. Among subjects who were currently HPV-16 DNA-negative, seroreactivity odds ratios increased from 2.9 for 2-5 male sex partners (vs. 0 or 1) to 5.4 for 6-9 partners and 14.0 for ≤10. Thus, prior cervical infection may be a major determinant of seroreactivity in HPV-16 DNA-negative women. This trend was not observed in HPV-16 DNA-positive subjects. Seroreactivity was independently associated with oral contraceptive use, particularly in HPV-16 DNA-negative subjects with use for ≤10 years. Consequently, a possible role for virus-steroid hormone interactions in seroconversion is suggested.",
author = "L. Wideroff and Schiffman, {M. H.} and R. Hoover and Tarone, {R. E.} and B. Nonnenmacher and N. Hubbert and R. Kirnbauer and Greer, {C. E.} and Lorincz, {A. T.} and Manos, {M. M.} and Glass, {A. G.} and Scott, {D. R.} and Sherman, {Mark E.} and J. Buckland and D. Lowy and J. Schiller",
year = "1996",
language = "English (US)",
volume = "174",
pages = "937--943",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 virus-like particles in cervical HPV-16 DNA-positive and - negative women

AU - Wideroff, L.

AU - Schiffman, M. H.

AU - Hoover, R.

AU - Tarone, R. E.

AU - Nonnenmacher, B.

AU - Hubbert, N.

AU - Kirnbauer, R.

AU - Greer, C. E.

AU - Lorincz, A. T.

AU - Manos, M. M.

AU - Glass, A. G.

AU - Scott, D. R.

AU - Sherman, Mark E.

AU - Buckland, J.

AU - Lowy, D.

AU - Schiller, J.

PY - 1996

Y1 - 1996

N2 - The epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 L1/L2 virus-like particles (VLPs) were assessed separately in HPV-16 DNA-positive and -negative women participating in a nested case- control study of incident cervical neoplasia. Seventy-four women with cervical HPV-16 DNA and 656 cytologically normal HPV-16 DNA-negative subjects were interviewed and tested at two time points for viral DNA and once (at the later time) for VLP seroreactivity. Among subjects who were currently HPV-16 DNA-negative, seroreactivity odds ratios increased from 2.9 for 2-5 male sex partners (vs. 0 or 1) to 5.4 for 6-9 partners and 14.0 for ≤10. Thus, prior cervical infection may be a major determinant of seroreactivity in HPV-16 DNA-negative women. This trend was not observed in HPV-16 DNA-positive subjects. Seroreactivity was independently associated with oral contraceptive use, particularly in HPV-16 DNA-negative subjects with use for ≤10 years. Consequently, a possible role for virus-steroid hormone interactions in seroconversion is suggested.

AB - The epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 L1/L2 virus-like particles (VLPs) were assessed separately in HPV-16 DNA-positive and -negative women participating in a nested case- control study of incident cervical neoplasia. Seventy-four women with cervical HPV-16 DNA and 656 cytologically normal HPV-16 DNA-negative subjects were interviewed and tested at two time points for viral DNA and once (at the later time) for VLP seroreactivity. Among subjects who were currently HPV-16 DNA-negative, seroreactivity odds ratios increased from 2.9 for 2-5 male sex partners (vs. 0 or 1) to 5.4 for 6-9 partners and 14.0 for ≤10. Thus, prior cervical infection may be a major determinant of seroreactivity in HPV-16 DNA-negative women. This trend was not observed in HPV-16 DNA-positive subjects. Seroreactivity was independently associated with oral contraceptive use, particularly in HPV-16 DNA-negative subjects with use for ≤10 years. Consequently, a possible role for virus-steroid hormone interactions in seroconversion is suggested.

UR - http://www.scopus.com/inward/record.url?scp=19244363100&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19244363100&partnerID=8YFLogxK

M3 - Article

C2 - 8896493

AN - SCOPUS:19244363100

VL - 174

SP - 937

EP - 943

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 5

ER -